China is actively building a dual-circulation development pattern. While strengthening the internal driving force of economic growth, China is positioned to further open to the outside world, carrying out more and more measures to bridge markets at home and abroad, so as to provide more impetus for world economic recovery. This has also provided unprecedented opportunities for foreign enterprises to seek development in China.

The Guangdong-Hong Kong-Macao Greater Bay Area (GBA) holds a unique status and advantages in the current economic landscape. With its advantages in world-class medical science, IT and health services; its position as the second-biggest biotech fundraising hub in the world; as well as new policies to foster scientific exchange and health innovation; GBA brings AstraZeneca great opportunities to leverage our global resources and strong innovative power to build an ecosystem of collaboration and foster a new wave of world-class developments to benefit the healthcare industry and patients around the world.